Recent Quotes (30 days)

You have no recent quotes
chg | %

Cascadian Therapeutics Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

CASC 3.88 -0.11 (-2.76%)
price chart
Cascadian Therapeutics Announces Stockholders and Board of Directors Approve ...
23, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that at a special meeting held on November 18, 2016, stockholders voted to approve a proposal authorizing the board of ...
Cascadian Therapeutics (CASC) Approves 1-for-6 Reverse Stock Split  StreetInsider.com
Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in ...
“Our interactions with regulators in the U.S. and Europe continue to support the design of our pivotal trial as a registrational pathway for tucatinib in both regions,” said Marc Lesnick, Ph.
Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress
05, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for its investigational drug portfolio in addition to several anticipated key objectives ...
Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President ...
04, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the appointment of Marc L. Lesnick, Ph.
Cascadian Therapeutics Reports Second Quarter 2017 Financial Results
08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2017, and provided an update on tucatinib, an investigational ...
Cascadian Therapeutics' (CASC) CEO Scott Myers On Q2 2017 Results ...  Seeking Alpha
Cascadian Therapeutics Inc (USA) (CASC) Analysts See $-0.25 EPS  Finance News Daily
Cascadian Therapeutics, Inc. (CASC) Rating Reiterated by Cantor Fitzgerald
Cascadian Therapeutics logo Cascadian Therapeutics, Inc. (NASDAQ:CASC)'s stock had its “hold” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, September 11th.
Cascadian Therapeutics (USA) (CASC) Reaches $3.86 After 5.00% Down Move ...  Herald KS
How Technical Indicators Have Come Out? – Cascadian Therapeutics, Inc. (CASC ...  Post Analyst
Cascadian Therapeutics: Worth Much More Than The Present Share Price
Despite misgivings about management, the company possesses a promising clinical candidate in tucatinib that is worth much more than the present valuation.
Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on ...
SEATTLE, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter financial results after the close of the U.S. financial markets ...
Cascadian Therapeutics (CASC): Positive Momentum for Metastatic Breast ...  Equities.com
BRIEF-Mark Lampert says resigning from Cascadian Therapeutics' board
BRIEF-Mark Lampert says resigning from Cascadian Therapeutics' board. Jan 17 Cascadian Therapeutics Inc. * Mark Lampert- On Jan 17, submitted letter to Cascadian Therapeutics, resigning from co's board, effective immediately - SEC filing.
Here's Why Cascadian Therapeutics Inc (USA) (CASC) Shares Tumble 11%
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock and Series E convertible preferred stock in concurrent but separate underwritten public offerings.
Cascadian Therapeutics Announces Proposed Concurrent Public Offerings of ...  GlobeNewswire (press release)